Verastem posts updated corporate presentation on RAS/MAPK pipeline; no new financial data

Verastem, Inc.

Corporate presentation dated May 7, 2026, furnished as Exhibit 99.1.
Presentation titled 'Delivering Novel Therapies for RAS/MAPK Pathway-Driven Cancers'.
No specific financial results, guidance, or material developments disclosed.
Presentation available on company website for investor reference.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.